Medicine & Life Sciences
Daclizumab
100%
siplizumab
92%
Adult T Cell Leukemia Lymphoma
81%
Therapeutics
41%
Alemtuzumab
41%
Hodgkin Disease
40%
T-Lymphocytes
29%
Yttrium
26%
Survivin
26%
Yttrium-90
23%
Large Granular Lymphocytic Leukemia
22%
Radioisotopes
20%
Antibodies
16%
Monoclonal Antibodies
15%
Human Herpesvirus 4
15%
Non-Hodgkin's Lymphoma
15%
Interleukin-2
15%
Neoplasms
12%
Maximum Tolerated Dose
11%
Interleukin-9
10%
Rituximab
10%
Clinical Trials, Phase I
9%
Clinical Trials
8%
Blood Cell Count
8%
T-Cell Lymphoma
8%
Interleukin-2 Receptor alpha Subunit
8%
Apoptosis
8%
Virus Diseases
7%
Antibodies, Monoclonal, Humanized
7%
Fc Receptors
7%
Lymphoma
7%
Leukocyte Count
7%
Stem Cell Transplantation
7%
Cytokines
7%
B-Lymphocytes
7%
Interleukin-2 Receptors
7%
Leukemia
6%
Bexarotene
6%
Chronic Disease
6%
Interleukin-2 Receptor beta Subunit
6%
Apoptosis Regulatory Proteins
6%
Animal Models
5%
Blood Cells
5%
Oligonucleotide Array Sequence Analysis
5%
Interleukin-15
5%